The commercial distribution of ANKTIVA commenced in May 2024, and the company believes it has the potential to become a ...

ImmunityBio (IBRX) delivered earnings and revenue surprises of -25% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...